2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer

SAN FRANCISCO, and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...

InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025

InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025

NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05379946)...

O-RAN ALLIANCE Global PlugFest Spring 2025 Demonstrated Steady Evolution of the O-RAN Ecosystem

O-RAN ALLIANCE Global PlugFest Spring 2025 Demonstrated Steady Evolution of the O-RAN Ecosystem

O-RAN ALLIANCE Global PlugFests focus on testing and integration to accelerate the development of O-RAN based products and solutions The O-RAN Global PlugFest Spring 2025 advanced O-RAN technology and procedures for testing, deployment and operation...

China's HER2-Targeted ADC Trastuzumab Rezetecan Gains NMPA Approval for HER2-Mutant NSCLC

China's HER2-Targeted ADC Trastuzumab Rezetecan Gains NMPA Approval for HER2-Mutant NSCLC

SHANGHAI, May 29, 2025 /PRNewswire/ -- The National Medical Products Administration has recently granted approval for Trastuzumab rezetecan, China's first domestically developed antibody-drug conjugate (ADC), for treatment of adult patients with...

French Cream: The Secret Ingredient to Perfect Desserts and Culinary Excellence

French Cream: The Secret Ingredient to Perfect Desserts and Culinary Excellence

Renowned for its richness, purity, and versatility, French cream remains the preferred choice of chefs and culinary artisans worldwide. SINGAPORE, May 26, 2025 /PRNewswire/ -- From the lush pastures of Normandy to the culinary capital of Paris,...

Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation

Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation

CHENGDU, China, May 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed...

BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth

BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth

International recognition of quality system with GMP-compliance in the key markets of Brazil, Indonesia, Egypt, Colombia and Argentina Passed its first-ever on-site PIC/S audit, reinforcing its strong commitment to stringent international regulatory...

Modern Dairy Wins Six Awards in Extel's 2025 Asia (ex-Japan) Executive Team Rankings

Modern Dairy Wins Six Awards in Extel's 2025 Asia (ex-Japan) Executive Team Rankings

HONG KONG, May 20, 2025 /PRNewswire/ -- On May 20, the prestigious financial magazine "Extel" (formerly "Institutional Investor") officially announced the results of the "2025 Asia (ex-Japan) Executive Team-SMID" rankings. The survey assessed and...

Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition

Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition

Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imaging sites SEOUL, South Korea, May 19, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider...

AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through

AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through

HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • menu
    menu